Characterization of CFTR mutations in people with cystic fibrosis and severe liver disease who are not eligible for CFTR modulators
Journal of Cystic Fibrosis · 2023
DOI: 10.1016/j.jcf.2023.01.012 ↗Kurz gefasst
Fachartikel in der Zeitschrift Journal of Cystic Fibrosis, 2023. Verfasst von Carla Colombo und 16 weiteren Autor:innen. Beteiligte Einrichtung: IRCCS Ca' Granda Ospedale Maggiore Policlinico, Milan, Italy; Università degli Studi di Milano, Department of Pathophysiology and Transplantation, Mi…. Hauptthemen laut MEDLINE: Cystic Fibrosis, Hypertension, Portal. Die Arbeit wurde bisher 9-mal zitiert (Crossref) und nennt 15 Literaturangaben.
Abstract (Originalsprache)
Cystic-fibrosis-related liver disease (CFLD) is a variable phenotype of CF. The severe CFLD variant with cirrhosis or portal hypertension has a poor prognosis and life expectancy. CFTR modulator therapies are now available for people with CF and eligibility for such treatment is based on their CFTR genotype. We evaluated the genetic eligibility for elexacaftor, tezacaftor, ivacaftor (ETI), and ivacaftor (IVA) monotherapy in a previously reported CF cohort of 1591 people with CF of whom 171 with severe CFLD. Based on their CFTR mutations, 13% (N=184/1420) of subjects without CFLD and 11% (N=19/171) of those with severe CFLD are not eligible for either ETI or IVA therapy. The non-eligible patients without CFLD or with severe CFLD can currently not take advantage of the potential benefits of these new treatments. Although this study cannot provide any data regarding the effect of ETI or IVA on the progression of severe CFLD, the consequences for ineligibility of patients with extreme liver phenotype may be even more significant because of their poorer disease risk profile.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- IRCCS Ca' Granda Ospedale Maggiore Policlinico, Milan, Italy; Università degli Studi di Milano, Department of Pathophysiology and Transplantation, Milan, Italy. Electronic address: carla.colombo@unimi.it.
- QIMR Berghofer Medical Research Institute, Brisbane, Australia.
- Queen Silvia Children's Hospital, Gothenburg, Sweden.
- IRCCS Ca' Granda Ospedale Maggiore Policlinico, Milan, Italy.
- Ospedale Pediatrico Bambino Gesù, Rome, Italy.
- City Children's Hospital N1, Yaroslavl, Russia.
Zitieren
APA
Colombo, C., Ramm, G. A., Lindblad, A., Corti, F., Porcaro, L., Alghisi, F., Asherova, I., Evans, H., Kashirskaya, N., Kondratyeva, E., Lewindon, P. J., de Monestrol, I., Oliver, M., Ooi, C. Y., Padoan, R., Shankar, S., & Alicandro, G. (2023). Characterization of CFTR mutations in people with cystic fibrosis and severe liver disease who are not eligible for CFTR modulators. Journal of Cystic Fibrosis. https://doi.org/10.1016/j.jcf.2023.01.012
Vancouver
Colombo C, Ramm GA, Lindblad A, Corti F, Porcaro L, Alghisi F, et al. Characterization of CFTR mutations in people with cystic fibrosis and severe liver disease who are not eligible for CFTR modulators. Journal of Cystic Fibrosis. 2023. doi:10.1016/j.jcf.2023.01.012
BibTeX
@article{Colombo2023,
author = {Colombo, Carla and Ramm, Grant A and Lindblad, Anders and Corti, Fabiola and Porcaro, Luigi and Alghisi, Federico and Asherova, Irina and Evans, Helen and Kashirskaya, Nataliya and Kondratyeva, Elena and Lewindon, Peter J and de Monestrol, Isabelle and Oliver, Mark and Ooi, Chee Y and Padoan, Rita and Shankar, Sahana and Alicandro, Gianfranco},
title = {Characterization of CFTR mutations in people with cystic fibrosis and severe liver disease who are not eligible for CFTR modulators},
journal = {Journal of Cystic Fibrosis},
year = {2023},
doi = {10.1016/j.jcf.2023.01.012}
}
EUVIMED